MEDICENNA THERAPEUTICS CORP (MDNA)
CA58490H1073 - Common Stock
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a...
Dear LUNR Stock Fans, Mark Your Calendars for Jan. 12
Intuitive Machines stock is rising on Monday after the company announced plans for a lunar mission launch in January 2024.
Why Is Medicenna Therapeutics (MDNA) Stock Down Today?
Medicenna Therapeutics stock is falling on Monday after the company announced that shares of MDNA will be delisted from the Nasdaq.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage!
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
The Company’s listing on the Toronto Stock Exchange will not be impacted...
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual...
Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)
TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage...
Medicenna Therapeutics appoints Gardner as CMO (NASDAQ:MDNA)
Medicenna Therapeutics announces the appointment of Humphrey Gardner as Chief Medical Officer (CMO), bringing his experience in advancing novel cancer...
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
Dr. Gardner brings over 30 years of experience leading clinical development to support innovative oncology programs and translational research at global...
Medicenna Announces Results of Annual and Special Meeting of Shareholders
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage...
Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage...
Medicenna Therapeutics gets new CFO (NASDAQ:MDNA)
Clinical-stage immunotherapy company Medicenna Therapeutics (MDNA) names Jeff Caravella as CFO.Most recently, he served as CFO at Biotheryx, where he led the finance, investor...
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science...
Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent.Brent Meadows, MBA, joins as Chief...
Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study
- Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities - Late-stage pancreatic cancer patient...
Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee
Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari...
Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023
TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a...
Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled “Interleukin-2 Fusion Proteins and Uses Thereof.”The patent covers a method...
Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined...
Medicenna Presents at National Brain Tumor Society's Research Round Table
Medicenna's President and CEO, Dr. Fahar Merchant, was invited to participate and present at the Brain Cancer Research Roundtable organized by the National...
Medicenna Extends Period to Exercise Certain Warrants
TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical...
Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights
MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response continuing for over 40 weeks...
Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
TORONTO and HOUSTON, April 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical...
Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
TORONTO and HOUSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical...
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
-- IL-13 Superkines provide a versatile strategy for targeted delivery of anti-cancer agents to IL-13Rα2, which is overexpressed in many solid tumors but...
Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study
- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts ...
Medicenna Announces Upcoming Presentation at the AACR Annual Meeting
TORONTO and HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a...
Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference
TORONTO and HOUSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a...
Medicenna Establishes At-the-Market Sales Facility
TORONTO and HOUSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical...
Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights
Phase 1/2 ABILITY study advancing to sixth dose escalation cohort following positive review of safety and pharmacodynamic data from fifth cohort Initial...
Medicenna to Present at the 2023 Guggenheim Oncology Conference
TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a...
Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023
TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical...